Phase 2 N=50 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis
Primary: Change in Liver Fat as Measured by MRI-PDFF — 15.0; 18.5; 11.6; 16.4 percentage of total fat
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=72 Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants
Phase 2 N=55 R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Stage IV Prostate Cancer
Primary: Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles — 22 percentage of participants
Phase 2 N=20 Hydromorphone and C-section
Postoperative Pain
Primary: Pain Scores, Visual Analogue Pain Scale — 2.75 units on a scale
Phase 2 N=85 Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas
Depressive Disorder · Depression
Primary: Change in Severity of Depression Using Hamilton Depression Rating Scale — 20.83; 19.23; 16.71; 17.27 units on a scale — p==.001
Phase 2 N=15 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Phase 2 N=101 Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Pre-hypertension
Primary: Change in Disease Score (DS) Among the Treatment Groups — -2.48; -2.29; -2.38; -0.96 Overall Rasmussen Disease Score Change
Phase 2 N=62 Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence
Cocaine Dependence
Primary: Maximum Days of Continuous Cocaine Abstinence — 42.9; 46.6 Days
Phase 2 N=80 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Ovarian Cancer · Epithelial Ovarian Cancer · Fallopian Tube Cancer
Primary: Maximum Tolerable Dose (MTD) Belinostat, Part A, — 1000 mg/m2
Phase 2 N=71 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Phase 2 N=60 A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 42; 48 percentage of participants
Phase 2 N=3 Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton Syndrome
Primary: Blood Pimecrolimus Levels — 0; 0; 0.312; 1.260 ng/mL
Phase 2 N=31 Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.
Congenital Venous Malformation
Primary: Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax) — 0.0604; 0.202 g/L
Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
Phase 2 N=300 Multisite Controlled Trial of Cocaine Vaccine
Cocaine Dependence
Primary: Cocaine Abstinence During Weeks 9 to 16 Inclusive — 21; 30 participants